Citation: | SHAO Rong, YIN Tianhong. Charging system in US PDUFA with reference to speeding up drug evaluation process of China[J]. Journal of China Pharmaceutical University, 2014, 45(3): 281-285. DOI: 10.11665/j.issn.1000-5048.20140305 |
[1] |
MENET.Representative called for an increase in drug evaluation fee to ease the staff burden On drug evaluation[EB/OL].[2014-03-10].http://www.menet.com.cn/Articles/information/201403/201403100858595859_110449.shtml.
|
[2] |
FDA.How many people are employed by FDA and in what areas do they work[EB/OL] ?[2014-03-23].http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/BudgetReports/UCM301553.pdf.
|
[3] |
Cantor DJ. Prescription drug user fee act of 1992: effects on bringing new drugs to market[EB/OL].[2014-04-29].http://digital.library.unt.edu/ark:/67531/metacrs416/m1/1/high_res_d/97-838e_1997Sep12.pdf.
|
[4] |
Olson MK. The risk we bear: the effects of review speed and industry user fees on new drug safety[J].J Health Eco,2008,27(2):175-200.
|
[5] |
FDA.PDUFA Performance Reports[EB/OL].[2014-03-23].http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/ucm2007449.htm.
|
[6] |
Thaul S.Prescription Drug User Fee Act(PDUFA):2012 Reauthorization as PDUFA V[EB/OL].[2014-01-04].http://www.fas.org/sgp/crs/misc/R42366.pdf.
|
[7] |
Establishment of prescription drug user fee rates for fiscal year 2002[EB/OL].[2014-01-04].http://www.gpo.gov/fdsys/pkg/FR-2002-01-16/pdf/02-1068.pdf.
|
[8] |
FDA.Frequently asked questions on prescription drug user fees[EB/OL].[2014-01-04].http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm069943.htm#top.
|
[9] |
FDA.FY 1995 PDUFA performance report[EB/OL].[2014-01-04].http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/ucm117257.htm.
|
[10] |
Kronquist AR.The prescription drug user fee act:history and reauthorization issues for 2012[EB/OL].[2014-01-04].http://www.heritage.org/research/reports/2011/12/the-prescription-drug-user-fee-act-history-and-reauthorization-issues-for-2012.
|
[11] |
Thaul S.The prescription drug user fee act(PDUFA):background and Issues for PDUFA IV reauthorization[EB/OL].[2014-4-29].http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=11595.
|
[12] |
GAO.Effect of user fees on drug approval times,withdrawals,and other agency activities[EB/OL].[2014-01-04].http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/ucm117257.htm.
|
[13] |
LIU Peng.Commercialization of quasi-public service——The disputes on drug evaluation financing system in FDA[J].China Prescr Drug(中国处方药),2007(6):8-9.
|